Table 5.
Sensitivity analysis replacing the number of drugs with specific agents in the multiple logistic regression for the prevalence of non-proliferative diabetic retinopathy in patients with type 2 diabetes
| Model 2 | Model 3 | Model 4 | ||||
|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | p value | Adjusted OR (95% CI) | p value | Adjusted OR (95% CI) | p value | |
| Sulfonylureas | 1.84 (1.50, 2.24) | < 0.001 | – | – | ||
| Biguanides | 1.33 (1.13, 1.56) | < 0.001 | – | – | ||
| α-Glucosidase inhibitors | 1.15 (0.98, 1.34) | 0.091 | – | – | ||
| Glinides | 1.25 (0.94, 1.66) | 0.128 | – | – | ||
| Thiazolidinediones | 1.12 (0.93, 1.34) | 0.234 | ||||
| Angiotensin receptor blockers | – | 1.21 (1.03, 1.41) | 0.021 | – | ||
| Angiotensin converting enzyme inhibitors | – | 0.99 (0.77, 1.28) | 0.950 | – | ||
| Ca blockers | – | 1.30 (1.10, 1.54) | 0.002 | – | ||
| Statin | – | – | 0.79 (0.68, 0.92) | 0.002 | ||
| Fibrate | – | – | 0.76 (0.56, 1.06) | 0.105 | ||
Adjusted for other covariates in Model 1
OR odds ratio, CI confidence interval